Saltar al contenido
Merck
Todas las fotos(2)

Documentos

05-796

Sigma-Aldrich

Anti-Akt1/PKBα Antibody, clone AW24, rabbit monoclonal

clone AW24, Upstate®, from rabbit

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(2)

About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

rabbit

Quality Level

100

antibody form

purified antibody

antibody product type

primary antibodies

clone

AW24, monoclonal

species reactivity

human, mouse, rat

manufacturer/tradename

Upstate®

technique(s)

immunoprecipitation (IP): suitable
western blot: suitable

isotype

IgG

NCBI accession no.

NM_005163

UniProt accession no.

P31749

shipped in

dry ice

target post-translational modification

unmodified

Gene Information

human ... AKT1(207)

Specificity

Akt1/PKBα

Immunogen

Peptide (C-RPHFPQFSYSASGTA) corresponding to the C-terminal (residues 466-480) of rat Akt1/PKBα

Application

Detect Akt1/PKBα using this Anti-Akt1 Antibody, clone AW24 validated for use in IP & WB.
Research Category
Signaling
Research Sub Category
PI3K, Akt, & mTOR Signaling

Quality

routinely evaluated by immunoblot on RIPA lysates from human HEK293 cells

Target description

~60kDa

Physical form

0.1M Tris-glycine, pH 7.4, 0.15M NaCl, 0.05% sodium azide before the addition of glycerol to 30%
Format: Purified
Protein A purified

Storage and Stability

2 years at -20°C

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Herramienta de selección de productos.

Optional

Referencia del producto
Descripción
Precios

Storage Class

10 - Combustible liquids

wgk_germany

WGK 1

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Sumiko Watanabe et al.
Cytotechnology, 71(1), 219-229 (2019-01-04)
A proposed mechanism underlying the effect of bacillus Calmette-Guérin (BCG) treatment for bladder cancer cells is as follows: BCG-induced crosslinking of cell-surface receptors results in the activation of signaling cascades, including cell-cycle regulators. However, the clinical significance of cell-cycle regulators
Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A/C gene mutation.
Choi, JC; Muchir, A; Wu, W; Iwata, S; Homma, S; Morrow, JP; Worman, HJ
Science Translational Medicine null
Santhanalakshmi Sundaramurthy et al.
Neuropharmacology, 113(Pt A), 281-292 (2016-11-05)
Kappa opioid receptor (KOR) agonists produce dysphoria and psychotomimesis. While KOR agonists produce pro-depressant-like effects, KOR antagonists produce anti-depressant-like effects in rodent models. The cellular mechanisms and downstream effector(s) by which KOR ligands produce these effects are not clear. KOR
Chih-Jen Cheng et al.
Journal of the American Society of Nephrology : JASN, 22(3), 460-471 (2011-03-01)
WNK kinases stimulate endocytosis of ROMK channels to regulate renal K+ handling. Phosphatidylinositol 3-kinase (PI3K)-activating hormones, such as insulin and IGF 1, phosphorylate WNK1, but how this affects the regulation of ROMK abundance is unknown. Here, serum starvation of ROMK-transfected
Toshitaka Uehara et al.
Cytotechnology, 75(1), 49-62 (2023-01-31)
The standard treatment for non-muscle-invasive bladder cancer is intravesical Bacillus Calmette-Guérin (BCG) therapy, which is considered the only intravesical therapy that reduces the risk of progression to muscle-invasive cancer. BCG unresponsiveness, in which intravesical BCG therapy is ineffective, has become
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico